biostudies-literatureRinnerthaler Gmundipharma international17588359211042301https://www.ebi.ac.uk/biostudies/studies/S-EPMC8529308biostudies-literatureUnknown13<h4>Background</h4>Bendamustine, a medication approved for the treatment of indolent non-Hodgkin lymphoma, has already shown anticancer activity in metastatic breast cancer (MBC). Here, we present the results of a phase II trial of bendamustine in combination with capecitabine in pre-treated patients with MBC.<h4>Patients and methods</h4>AGMT MBC-6 is a multicentre, open-label, single-arm phase II study in HER2-negative MBC. All patients were pre-treated with anthracyclines and/or taxans and had measurable disease. Patients received per os 1000 mg/m² capecitabine twice daily on days 1 to 14 in combination with 80 mg/m² bendamustine intravenously on days 1 and 8 of a 3-week cycle for a maximum of eight cycles, followed by a capecitabine maintenance therapy. The primaryTherapeutic advances in medical oncologyCapecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6).PMC8529308unrestricted grantHubalek MPetru EPetzer ASchmitt CAUlmer HGreil RBalic MHauser-Kronberger CAndel JMelchardt TGampenrieder SPSandholzer MRinnerthaler GfalseCapecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6).<h4>Background</h4>Bendamustine, a medication approved for the treatment of indolent non-Hodgkin lymphoma, has already shown anticancer activity in metastatic breast cancer (MBC). Here, we present the results of a phase II trial of bendamustine in combination with capecitabine in pre-treated patients with MBC.<h4>Patients and methods</h4>AGMT MBC-6 is a multicentre, open-label, single-arm phase II study in HER2-negative MBC. All patients were pre-treated with anthracyclines and/or taxans and had measurable disease. Patients received per os 1000 mg/m² capecitabine twice daily on days 1 to 14 in combination with 80 mg/m² bendamustine intravenously on days 1 and 8 of a 3-week cycle for a maximum of eight cycles, followed by a capecitabine maintenance therapy. The primary2021-01-01T00:00:00Z20212026-05-09T03:43:51.523Z2025-02-19T01:44:28.997ZS-EPMC85293083469124310.1177/17588359211042301